March 12, 2015
Bernstein Liebhard LLP today announced that it is investigating possible claims against Inogen, Inc. (“Inogen” or the “Company”) (NASDAQ: INGN). The investigation concerns whether Inogen and certain of its officers and/or directors have violated
Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Inogen is a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
On March 11, 2015, Inogen issued a press release postponing its earnings call for the fourth quarter and full year 2014 as a result of an ongoing internal investigation. The Company announced that “during the first quarter of 2015 certain potential accounting matters were discovered by management, which prompted the Audit Committee, with the assistance of independent advisors, to commence an internal investigation. The Audit Committee is investigating whether there were any violations of the Company’s accounting policies associated with these potential accounting matters.”
In reaction to this news, Inogen’s stock price dropped by as much as 18.2% in morning trading on March 12, 2015.
If you lost money in Inogen, or are interested in discussing your rights as an Inogen shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or firstname.lastname@example.org.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs’ firms in the country.